Illumina has launched TruSight Tumor 170, which is a 170 gene sequencing solution to support the evolution of the tumor-profiling paradigm from a series of single-gene tests to a multi-analyte approach.

This assay is designed to support limited nucleic acid input from formalin-fixed, paraffin-embedded samples and facilitates efficient evaluation of biomarkers.

The device will begin production in early 2017. — Cynthia Jessup